BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3036884)

  • 21. [Histomorphologic changes in Jensen sarcoma following radiotherapy, titanocene dichloride treatment and combination therapy].
    Uhl J; Langrock K; Krieghoff B; Hambsch K
    Radiobiol Radiother (Berl); 1987; 28(1):51-7. PubMed ID: 3588859
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
    Köpf-Maier P; Hesse A
    J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
    Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Titanocene dichloride--the first metallocene with cancerostatic activity.
    Köpf H; Köpf-Maier P
    Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
    [No Abstract]   [Full Text] [Related]  

  • 25. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
    Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
    Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Titanium complexes in cancer treatment.
    Meléndez E
    Crit Rev Oncol Hematol; 2002 Jun; 42(3):309-15. PubMed ID: 12050022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced anti-cancer activities of some derivatives of titanocene dichloride.
    Boyles JR; Bair MC; Campling BG; Jain N
    J Inorg Biochem; 2001 Mar; 84(1-2):159-62. PubMed ID: 11330477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma.
    Köpf-Maier P; Köpf H
    Arzneimittelforschung; 1987 May; 37(5):532-4. PubMed ID: 3619974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
    Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
    Cancer Chemother Pharmacol; 1998; 42(5):415-7. PubMed ID: 9771957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTP Toxicology and Carcinogenesis Studies of Titanocene Dichloride (CAS No. 1271-19-8) in F344/N Rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1991 Sep; 399():1-182. PubMed ID: 12637960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects.
    Köpf-Maier P; Hesse B; Voigtländer R; Köpf H
    J Cancer Res Clin Oncol; 1980; 97(1):31-9. PubMed ID: 7400205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
    Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes.
    Chimento A; Saturnino C; Iacopetta D; Mazzotta R; Caruso A; Plutino MR; Mariconda A; Ramunno A; Sinicropi MS; Pezzi V; Longo P
    Bioorg Med Chem; 2015 Nov; 23(22):7302-12. PubMed ID: 26526741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of diethoxy-(1-phenyl-1,3-butanedionato) titanium (IV) in human tumour xenografts.
    Mattern J; Keppler B; Volm M
    Arzneimittelforschung; 1984; 34(10):1289-90. PubMed ID: 6549134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer activity and mode of action of titanocene C.
    Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
    Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A controlled release system of titanocene dichloride by electrospun fiber and its antitumor activity in vitro.
    Chen P; Wu QS; Ding YP; Chu M; Huang ZM; Hu W
    Eur J Pharm Biopharm; 2010 Nov; 76(3):413-20. PubMed ID: 20854905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of treosulfan in human lung carcinomas.
    Köpf-Maier P; Sass G
    Cancer Chemother Pharmacol; 1996; 37(3):211-21. PubMed ID: 8529280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of angiogenesis by the antitumor agent titanocene dichloride.
    Bastaki M; Missirlis E; Klouras N; Karakiulakis G; Maragoudakis ME
    Eur J Pharmacol; 1994 Jan; 251(2-3):263-9. PubMed ID: 7512041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity studies of Ti(IV) complexes: aqueous stability and cytotoxic properties in colon cancer HT-29 cells.
    Hernández R; Lamboy J; Gao LM; Matta J; Román FR; Meléndez E
    J Biol Inorg Chem; 2008 Jun; 13(5):685-92. PubMed ID: 18288505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.